

Multiple Sclerosis (MS) Drugs-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data

<https://marketpublishers.com/r/M88EB4E2E0EMEN.html>

Date: February 2018

Pages: 135

Price: US\$ 3,680.00 (Single User License)

ID: M88EB4E2E0EMEN

Abstracts

Report Summary

Multiple Sclerosis (MS) Drugs-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Multiple Sclerosis (MS) Drugs industry, standing on the readers' perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Worldwide and Top 20 Countries Market Size of Multiple Sclerosis (MS) Drugs 2013-2017, and development forecast 2018-2023

Main manufacturers/suppliers of Multiple Sclerosis (MS) Drugs worldwide and market share by regions, with company and product introduction, position in the Multiple Sclerosis (MS) Drugs market

Market status and development trend of Multiple Sclerosis (MS) Drugs by types and applications

Cost and profit status of Multiple Sclerosis (MS) Drugs, and marketing status

Market growth drivers and challenges

The report segments the global Multiple Sclerosis (MS) Drugs market as:

Global Multiple Sclerosis (MS) Drugs Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)

Asia Pacific (China, Japan, India, Southeast Asia and Australia)
Latin America (Brazil, Argentina and Colombia)
Middle East and Africa

Global Multiple Sclerosis (MS) Drugs Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Copaxone (Glatiramer Acetate, Copolymer 1)
Novantrone (Mitoxantrone)
Gilenya (Fingolimod, Fty720)
Aubagio (Teriflunomide)
Tecfidera (Dimethyl Fumarate)
Finategrast (Sb683699, T-0047)
Siponimod (Baf312)
Others

Global Multiple Sclerosis (MS) Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

RRMS
SPMS
PPMS
PRMS

Global Multiple Sclerosis (MS) Drugs Market: Manufacturers Segment Analysis (Company and Product introduction, Multiple Sclerosis (MS) Drugs Sales Volume, Revenue, Price and Gross Margin):

Bayer AG
Bayhill Therapeutics
Biogen Idec
Cinnagen
Daiichi Sankyo
Eli Lilly
Fast Forward Llc
Antisense Therapeutics
Apitope
Five Prime Therapeutics

Genmab
Artielle Immunotherapeutics
Genzyme
Glaxosmithkline
Gw Pharmaceuticals
Innate Immunotherapeutics

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF MULTIPLE SCLEROSIS (MS) DRUGS

- 1.1 Definition of Multiple Sclerosis (MS) Drugs in This Report
- 1.2 Commercial Types of Multiple Sclerosis (MS) Drugs
 - 1.2.1 Copaxone (Glatiramer Acetate, Copolymer 1)
 - 1.2.2 Novantrone (Mitoxantrone)
 - 1.2.3 Gilenya (Fingolimod, Fty720)
 - 1.2.4 Aubagio (Teriflunomide)
 - 1.2.5 Tecfidera (Dimethyl Fumarate)
 - 1.2.6 Finategrast (Sb683699, T-0047)
 - 1.2.7 Siponimod (Baf312)
 - 1.2.8 Others
- 1.3 Downstream Application of Multiple Sclerosis (MS) Drugs
 - 1.3.1 RRMS
 - 1.3.2 SPMS
 - 1.3.3 PPMS
 - 1.3.4 PRMS
- 1.4 Development History of Multiple Sclerosis (MS) Drugs
- 1.5 Market Status and Trend of Multiple Sclerosis (MS) Drugs 2013-2023
 - 1.5.1 Global Multiple Sclerosis (MS) Drugs Market Status and Trend 2013-2023
 - 1.5.2 Regional Multiple Sclerosis (MS) Drugs Market Status and Trend 2013-2023

CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Development of Multiple Sclerosis (MS) Drugs 2013-2017
- 2.2 Sales Market of Multiple Sclerosis (MS) Drugs by Regions
 - 2.2.1 Sales Volume of Multiple Sclerosis (MS) Drugs by Regions
 - 2.2.2 Sales Value of Multiple Sclerosis (MS) Drugs by Regions
- 2.3 Production Market of Multiple Sclerosis (MS) Drugs by Regions
- 2.4 Global Market Forecast of Multiple Sclerosis (MS) Drugs 2018-2023
 - 2.4.1 Global Market Forecast of Multiple Sclerosis (MS) Drugs 2018-2023
 - 2.4.2 Market Forecast of Multiple Sclerosis (MS) Drugs by Regions 2018-2023

CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES

- 3.1 Sales Volume of Multiple Sclerosis (MS) Drugs by Types
- 3.2 Sales Value of Multiple Sclerosis (MS) Drugs by Types

3.3 Market Forecast of Multiple Sclerosis (MS) Drugs by Types

CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Global Sales Volume of Multiple Sclerosis (MS) Drugs by Downstream Industry

4.2 Global Market Forecast of Multiple Sclerosis (MS) Drugs by Downstream Industry

CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

5.1 North America Multiple Sclerosis (MS) Drugs Market Status by Countries

5.1.1 North America Multiple Sclerosis (MS) Drugs Sales by Countries (2013-2017)

5.1.2 North America Multiple Sclerosis (MS) Drugs Revenue by Countries (2013-2017)

5.1.3 United States Multiple Sclerosis (MS) Drugs Market Status (2013-2017)

5.1.4 Canada Multiple Sclerosis (MS) Drugs Market Status (2013-2017)

5.1.5 Mexico Multiple Sclerosis (MS) Drugs Market Status (2013-2017)

5.2 North America Multiple Sclerosis (MS) Drugs Market Status by Manufacturers

5.3 North America Multiple Sclerosis (MS) Drugs Market Status by Type (2013-2017)

5.3.1 North America Multiple Sclerosis (MS) Drugs Sales by Type (2013-2017)

5.3.2 North America Multiple Sclerosis (MS) Drugs Revenue by Type (2013-2017)

5.4 North America Multiple Sclerosis (MS) Drugs Market Status by Downstream Industry (2013-2017)

CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

6.1 Europe Multiple Sclerosis (MS) Drugs Market Status by Countries

6.1.1 Europe Multiple Sclerosis (MS) Drugs Sales by Countries (2013-2017)

6.1.2 Europe Multiple Sclerosis (MS) Drugs Revenue by Countries (2013-2017)

6.1.3 Germany Multiple Sclerosis (MS) Drugs Market Status (2013-2017)

6.1.4 UK Multiple Sclerosis (MS) Drugs Market Status (2013-2017)

6.1.5 France Multiple Sclerosis (MS) Drugs Market Status (2013-2017)

6.1.6 Italy Multiple Sclerosis (MS) Drugs Market Status (2013-2017)

6.1.7 Russia Multiple Sclerosis (MS) Drugs Market Status (2013-2017)

6.1.8 Spain Multiple Sclerosis (MS) Drugs Market Status (2013-2017)

6.1.9 Benelux Multiple Sclerosis (MS) Drugs Market Status (2013-2017)

6.2 Europe Multiple Sclerosis (MS) Drugs Market Status by Manufacturers

6.3 Europe Multiple Sclerosis (MS) Drugs Market Status by Type (2013-2017)

- 6.3.1 Europe Multiple Sclerosis (MS) Drugs Sales by Type (2013-2017)
- 6.3.2 Europe Multiple Sclerosis (MS) Drugs Revenue by Type (2013-2017)
- 6.4 Europe Multiple Sclerosis (MS) Drugs Market Status by Downstream Industry (2013-2017)

CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 7.1 Asia Pacific Multiple Sclerosis (MS) Drugs Market Status by Countries
 - 7.1.1 Asia Pacific Multiple Sclerosis (MS) Drugs Sales by Countries (2013-2017)
 - 7.1.2 Asia Pacific Multiple Sclerosis (MS) Drugs Revenue by Countries (2013-2017)
 - 7.1.3 China Multiple Sclerosis (MS) Drugs Market Status (2013-2017)
 - 7.1.4 Japan Multiple Sclerosis (MS) Drugs Market Status (2013-2017)
 - 7.1.5 India Multiple Sclerosis (MS) Drugs Market Status (2013-2017)
 - 7.1.6 Southeast Asia Multiple Sclerosis (MS) Drugs Market Status (2013-2017)
 - 7.1.7 Australia Multiple Sclerosis (MS) Drugs Market Status (2013-2017)
- 7.2 Asia Pacific Multiple Sclerosis (MS) Drugs Market Status by Manufacturers
- 7.3 Asia Pacific Multiple Sclerosis (MS) Drugs Market Status by Type (2013-2017)
 - 7.3.1 Asia Pacific Multiple Sclerosis (MS) Drugs Sales by Type (2013-2017)
 - 7.3.2 Asia Pacific Multiple Sclerosis (MS) Drugs Revenue by Type (2013-2017)
- 7.4 Asia Pacific Multiple Sclerosis (MS) Drugs Market Status by Downstream Industry (2013-2017)

CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 8.1 Latin America Multiple Sclerosis (MS) Drugs Market Status by Countries
 - 8.1.1 Latin America Multiple Sclerosis (MS) Drugs Sales by Countries (2013-2017)
 - 8.1.2 Latin America Multiple Sclerosis (MS) Drugs Revenue by Countries (2013-2017)
 - 8.1.3 Brazil Multiple Sclerosis (MS) Drugs Market Status (2013-2017)
 - 8.1.4 Argentina Multiple Sclerosis (MS) Drugs Market Status (2013-2017)
 - 8.1.5 Colombia Multiple Sclerosis (MS) Drugs Market Status (2013-2017)
- 8.2 Latin America Multiple Sclerosis (MS) Drugs Market Status by Manufacturers
- 8.3 Latin America Multiple Sclerosis (MS) Drugs Market Status by Type (2013-2017)
 - 8.3.1 Latin America Multiple Sclerosis (MS) Drugs Sales by Type (2013-2017)
 - 8.3.2 Latin America Multiple Sclerosis (MS) Drugs Revenue by Type (2013-2017)
- 8.4 Latin America Multiple Sclerosis (MS) Drugs Market Status by Downstream Industry (2013-2017)

CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

9.1 Middle East and Africa Multiple Sclerosis (MS) Drugs Market Status by Countries

9.1.1 Middle East and Africa Multiple Sclerosis (MS) Drugs Sales by Countries (2013-2017)

9.1.2 Middle East and Africa Multiple Sclerosis (MS) Drugs Revenue by Countries (2013-2017)

9.1.3 Middle East Multiple Sclerosis (MS) Drugs Market Status (2013-2017)

9.1.4 Africa Multiple Sclerosis (MS) Drugs Market Status (2013-2017)

9.2 Middle East and Africa Multiple Sclerosis (MS) Drugs Market Status by Manufacturers

9.3 Middle East and Africa Multiple Sclerosis (MS) Drugs Market Status by Type (2013-2017)

9.3.1 Middle East and Africa Multiple Sclerosis (MS) Drugs Sales by Type (2013-2017)

9.3.2 Middle East and Africa Multiple Sclerosis (MS) Drugs Revenue by Type (2013-2017)

9.4 Middle East and Africa Multiple Sclerosis (MS) Drugs Market Status by Downstream Industry (2013-2017)

CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF MULTIPLE SCLEROSIS (MS) DRUGS

10.1 Global Economy Situation and Trend Overview

10.2 Multiple Sclerosis (MS) Drugs Downstream Industry Situation and Trend Overview

CHAPTER 11 MULTIPLE SCLEROSIS (MS) DRUGS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS

11.1 Production Volume of Multiple Sclerosis (MS) Drugs by Major Manufacturers

11.2 Production Value of Multiple Sclerosis (MS) Drugs by Major Manufacturers

11.3 Basic Information of Multiple Sclerosis (MS) Drugs by Major Manufacturers

11.3.1 Headquarters Location and Established Time of Multiple Sclerosis (MS) Drugs Major Manufacturer

11.3.2 Employees and Revenue Level of Multiple Sclerosis (MS) Drugs Major Manufacturer

11.4 Market Competition News and Trend

11.4.1 Merger, Consolidation or Acquisition News

11.4.2 Investment or Disinvestment News

11.4.3 New Product Development and Launch

CHAPTER 12 MULTIPLE SCLEROSIS (MS) DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

12.1 Bayer AG

12.1.1 Company profile

12.1.2 Representative Multiple Sclerosis (MS) Drugs Product

12.1.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of Bayer AG

12.2 Bayhill Therapeutics

12.2.1 Company profile

12.2.2 Representative Multiple Sclerosis (MS) Drugs Product

12.2.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of Bayhill Therapeutics

12.3 Biogen Idec

12.3.1 Company profile

12.3.2 Representative Multiple Sclerosis (MS) Drugs Product

12.3.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of Biogen Idec

12.4 Cinnagen

12.4.1 Company profile

12.4.2 Representative Multiple Sclerosis (MS) Drugs Product

12.4.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of Cinnagen

12.5 Daiichi Sankyo

12.5.1 Company profile

12.5.2 Representative Multiple Sclerosis (MS) Drugs Product

12.5.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of Daiichi Sankyo

12.6 Eli Lilly

12.6.1 Company profile

12.6.2 Representative Multiple Sclerosis (MS) Drugs Product

12.6.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of Eli Lilly

12.7 Fast Forward Llc

12.7.1 Company profile

12.7.2 Representative Multiple Sclerosis (MS) Drugs Product

12.7.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of Fast

Forward Llc

12.8 Antisense Therapeutics

12.8.1 Company profile

12.8.2 Representative Multiple Sclerosis (MS) Drugs Product

12.8.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of Antisense Therapeutics

12.9 Apitope

12.9.1 Company profile

12.9.2 Representative Multiple Sclerosis (MS) Drugs Product

12.9.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of Apitope

12.10 Five Prime Therapeutics

12.10.1 Company profile

12.10.2 Representative Multiple Sclerosis (MS) Drugs Product

12.10.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of Five Prime Therapeutics

12.11 Genmab

12.11.1 Company profile

12.11.2 Representative Multiple Sclerosis (MS) Drugs Product

12.11.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of Genmab

12.12 Artielle Immunotherapeutics

12.12.1 Company profile

12.12.2 Representative Multiple Sclerosis (MS) Drugs Product

12.12.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of Artielle Immunotherapeutics

12.13 Genzyme

12.13.1 Company profile

12.13.2 Representative Multiple Sclerosis (MS) Drugs Product

12.13.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of Genzyme

12.14 Glaxosmithkline

12.14.1 Company profile

12.14.2 Representative Multiple Sclerosis (MS) Drugs Product

12.14.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of Glaxosmithkline

12.15 Gw Pharmaceuticals

12.15.1 Company profile

12.15.2 Representative Multiple Sclerosis (MS) Drugs Product

12.15.3 Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin of Gw Pharmaceuticals

12.16 Innate Immunotherapeutics

CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF MULTIPLE SCLEROSIS (MS) DRUGS

13.1 Industry Chain of Multiple Sclerosis (MS) Drugs

13.2 Upstream Market and Representative Companies Analysis

13.3 Downstream Market and Representative Companies Analysis

CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF MULTIPLE SCLEROSIS (MS) DRUGS

14.1 Cost Structure Analysis of Multiple Sclerosis (MS) Drugs

14.2 Raw Materials Cost Analysis of Multiple Sclerosis (MS) Drugs

14.3 Labor Cost Analysis of Multiple Sclerosis (MS) Drugs

14.4 Manufacturing Expenses Analysis of Multiple Sclerosis (MS) Drugs

CHAPTER 15 REPORT CONCLUSION

CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE

16.1 Methodology/Research Approach

16.1.1 Research Programs/Design

16.1.2 Market Size Estimation

16.1.3 Market Breakdown and Data Triangulation

16.2 Data Source

16.2.1 Secondary Sources

16.2.2 Primary Sources

16.3 Reference

I would like to order

Product name: Multiple Sclerosis (MS) Drugs-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data

Product link: <https://marketpublishers.com/r/M88EB4E2E0EMEN.html>

Price: US\$ 3,680.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M88EB4E2E0EMEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

